limb amputation News
-
Effects of prosthetic limb prescription on 3-year mortality among Veterans with lower-limb amputation
Method: Retrospective observational study on 4,578 Veterans hospitalized for LLA and discharged 2003- 2004, looking at time to all-cause mortality from the amputation surgical date up to the 3 yr anniversary. Results: 1,300 (28.4%) persons received a prescription for a prosthetic limb within 1 yr after the surgical amputation. About 46% (n = 2,086) of all Veterans w LLA died within 3 yr of the ...
-
CARDIONOVUM announces the first Signature RCT patient enrollment
CARDIONOVUM announced today the first Signature Randomized Clinical Trial patient enrolment. On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled. Dr. Ralf Langhoff, P.I. of the study, stated “I believe that this randomized study will confirm, once more, the efficacy and the safety of the Legflow® DCB in the daily treatment of ...
-
Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
-
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius High Frequency Nerve Block System
Neuros Medical, Inc., announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel High-Frequency Nerve Block system as an aid in the management of chronic intractable pain of the lower limb of adult amputees. The FDA Breakthrough Device Program is intended to help patients and health care providers receive timely ...
-
Research Finds All-Cause Hospitalizations are Nearly Three Times More Likely During a Diabetic Foot Ulcer Episode
SOMERVILLE, Mass., January 18, 2022 — Podimetrics, a virtual care support company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which compared the health of individuals during and after periods of diabetic foot ulceration — open sores or wounds on the foot, which commonly occur among those with diabetes and are the ...
-
Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine
Vascuqen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. The worldwide, exclusive licenses include patent rights ...
-
Soundbite Medical Solutions Announces Issuance of a Fourth U.S. Patent Further Expanding Coverage of its Core Technology
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued US patent No. 11,065,645, entitled “Method and system for generating mechanical pulses”. The patent is directed to a ...
-
Soundbite Medical Solutions Receives FDA 510(k) Clearance for the SoundBite® Crossing System – Peripheral (14P)
Soundbite announces the company has received Food and Drug Administration (FDA) 510(k) clearance for the SoundBite® Crossing System - Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SoundBite Crossing System – Peripheral (14P) is a recanalization tool, designed to help physician’s placement of conventional guidewires or treatment devices in the intraluminal space ...
-
SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs
Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of ...
-
Soundbite Medical Solutions Announces Issuance of a Third U.S. Patent Expanding Coverage of its Core Technology
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,000,880, entitled “Mechanical Waveguide Provided With A Marker Thereon”. The patent is directed ...
-
Soundbite Medical Solutions Announces Issuance of Two New U.S. Patent Further Expanding Coverage of its Shock Wave Technology
Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued two additional US patents. Patent No. 11,419,619, entitled “Method and system for treating ...
-
Soundbite Medical’s Proprietary Shock Wave Technology Now Cracks Calcium In Germany, a Promising Solution for CLI Patients
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced the use of its novel Active Wire 0.014” platform at a prominent site in Germany with the successful treatment of patients suffering from heavily calcified lower limb chronic total ...
-
Soundbite Medical’s Shock Wave Technology Continues to Crack Through Severe Calcium with the Addition of its First US Site
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced the use of its novel Active Wire 0.014” platform at a first site in the United States in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily ...
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Reva medical announces closing of strategic financing
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. This funding was led by a global strategic investor with deep experience in medical devices, as well as BioStar Capital, and existing investors. Proceeds from the financing ...
-
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal ...
-
Hemostemix Announces Rick Groome as Special Advisor to the CEO
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce Mr. Richard (“Rick”) Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau ...
-
Study: Pathbreaking Technology Completely Eliminated Major Diabetic Amputations
Research conducted by Kaiser Permanente also found once-daily remote temperature monitoring with Podimetrics decreased overall resource utilization SOMERVILLE, Mass., October 14, 2020 — Podimetrics, a virtual care management company with the leading solution to help prevent costly and deadly diabetic amputations, today announced results from its latest study of patients at high risk of ...
-
Profusa Debuts Tissue-integrated Sensors for Long-term Continuous Monitoring of Body Chemistry at the Pioneers Festival in Vienna
Injectable biosensors that become one with the body’s tissue may one day replace the clinical lab for making our body chemistry continuously accessible for improved personal wellbeing in health and disease. Promising a new era in digital health, Profusa, Inc., based in South San Francisco, Calif., today debuted its injectable Lumee™ biosensor technology at the Pioneers ...
-
Hemostemix Announces Settlement Agreement
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce that it has entered into a settlement agreement (the “Settlement Agreement”) with Aspire Health Science, LLC ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you